WO2013033271A3 - Method to augment immune system in response to disease or injury - Google Patents

Method to augment immune system in response to disease or injury Download PDF

Info

Publication number
WO2013033271A3
WO2013033271A3 PCT/US2012/052944 US2012052944W WO2013033271A3 WO 2013033271 A3 WO2013033271 A3 WO 2013033271A3 US 2012052944 W US2012052944 W US 2012052944W WO 2013033271 A3 WO2013033271 A3 WO 2013033271A3
Authority
WO
WIPO (PCT)
Prior art keywords
insult
injury
disease
response
patient
Prior art date
Application number
PCT/US2012/052944
Other languages
French (fr)
Other versions
WO2013033271A2 (en
Inventor
Derren Barken
Israel Barken
Original Assignee
Derren Barken
Israel Barken
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Derren Barken, Israel Barken filed Critical Derren Barken
Publication of WO2013033271A2 publication Critical patent/WO2013033271A2/en
Publication of WO2013033271A3 publication Critical patent/WO2013033271A3/en
Priority to US13/970,537 priority Critical patent/US20140065629A1/en
Priority to US13/971,847 priority patent/US20140065098A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2046—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/58—Prostate

Abstract

In one example, the present invention comprises a deliberate insult or the recognition that an insult has occurred in a patient, which insult induces an immune recognition event. The T cell repertoire is catalogued from samples of the patient's lymphocytes from before and after the insult in order to detect and sequence the TCR alpha and beta loci of highly expanded T cell clonotypes. In some examples, this information is used in turn to generate autologous T cells or to create autologous genetically- engineered T cells, either of which include TCR sequences that target the individual's disease or injury, resulting in cure or amelioration of symptoms.
PCT/US2012/052944 2011-08-29 2012-08-29 Method to augment immune system in response to disease or injury WO2013033271A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US13/970,537 US20140065629A1 (en) 2012-08-29 2013-08-19 Methods of treating diseases
US13/971,847 US20140065098A1 (en) 2012-08-29 2013-08-21 Method to augment immune system in response to disease or injury

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161528657P 2011-08-29 2011-08-29
US61/528,657 2011-08-29

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/970,537 Continuation-In-Part US20140065629A1 (en) 2012-08-29 2013-08-19 Methods of treating diseases
US13/971,847 Continuation-In-Part US20140065098A1 (en) 2012-08-29 2013-08-21 Method to augment immune system in response to disease or injury

Publications (2)

Publication Number Publication Date
WO2013033271A2 WO2013033271A2 (en) 2013-03-07
WO2013033271A3 true WO2013033271A3 (en) 2013-05-10

Family

ID=47757162

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/052944 WO2013033271A2 (en) 2011-08-29 2012-08-29 Method to augment immune system in response to disease or injury

Country Status (1)

Country Link
WO (1) WO2013033271A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190300945A1 (en) 2010-04-05 2019-10-03 Prognosys Biosciences, Inc. Spatially Encoded Biological Assays
US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
GB201106254D0 (en) 2011-04-13 2011-05-25 Frisen Jonas Method and product
US20140356318A1 (en) * 2013-05-28 2014-12-04 Israel Barken Adoptive cell therapy with specific regulatory lymphocytes
US9879313B2 (en) 2013-06-25 2018-01-30 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
CN112472699A (en) 2013-07-26 2021-03-12 种族肿瘤学公司 Combination methods for improving the therapeutic benefit of bisantrene and derivatives
CN113186256A (en) 2015-04-10 2021-07-30 空间转录公司 Spatially differentiated, multiplexed nucleic acid analysis of biological samples
WO2019051335A1 (en) * 2017-09-07 2019-03-14 Juno Therapeutics, Inc. Methods of identifying cellular attributes related to outcomes associated with cell therapy
WO2020243579A1 (en) 2019-05-30 2020-12-03 10X Genomics, Inc. Methods of detecting spatial heterogeneity of a biological sample
CN116249785A (en) 2020-06-02 2023-06-09 10X基因组学有限公司 Space transcriptomics for antigen-receptor
EP4025692A2 (en) 2020-06-02 2022-07-13 10X Genomics, Inc. Nucleic acid library methods
WO2021252499A1 (en) 2020-06-08 2021-12-16 10X Genomics, Inc. Methods of determining a surgical margin and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010085816A (en) * 1998-09-17 2001-09-07 제넨테크, 인크. Compositions and Methods for the Treatment of Immune Related Diseases
WO2006083969A2 (en) * 2005-02-01 2006-08-10 Amnis Corporation Blood analysis using a flow imaging cytometer
US20070117134A1 (en) * 2005-11-18 2007-05-24 Kou Zhong C Method for detection and quantification of T-cell receptor Vbeta repertoire
US20110207134A1 (en) * 2008-11-07 2011-08-25 Sequenta, Inc. Monitoring health and disease status using clonotype profiles

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010085816A (en) * 1998-09-17 2001-09-07 제넨테크, 인크. Compositions and Methods for the Treatment of Immune Related Diseases
WO2006083969A2 (en) * 2005-02-01 2006-08-10 Amnis Corporation Blood analysis using a flow imaging cytometer
US20070117134A1 (en) * 2005-11-18 2007-05-24 Kou Zhong C Method for detection and quantification of T-cell receptor Vbeta repertoire
US20110207134A1 (en) * 2008-11-07 2011-08-25 Sequenta, Inc. Monitoring health and disease status using clonotype profiles

Also Published As

Publication number Publication date
WO2013033271A2 (en) 2013-03-07

Similar Documents

Publication Publication Date Title
WO2013033271A3 (en) Method to augment immune system in response to disease or injury
Gammazza et al. Human molecular chaperones share with SARS-CoV-2 antigenic epitopes potentially capable of eliciting autoimmunity against endothelial cells: possible role of molecular mimicry in COVID-19
Nguyen et al. Origins of CD 4+ circulating and tissue‐resident memory T‐cells
Kalekar et al. Relationship between CD4 regulatory T cells and anergy in vivo
Purcell et al. Immunity to fish rhabdoviruses
WO2013084076A3 (en) System and method for evaluating and marketing clinical research centers
WO2011153543A3 (en) Systems and methods of predicting a subject's medical outcome
WO2014005040A3 (en) Automated clinical evidence sheet workflow
WO2012116334A3 (en) Methods and systems for assessing latent traits using probabilistic scoring
JP2016506750A5 (en)
Chen et al. Experimental evidence that mutated-self peptides derived from mitochondrial DNA somatic mutations have the potential to trigger autoimmunity
Van Kaer Comeback kids: CD8+ suppressor T cells are back in the game
Kaufmann T-Cell paradigms in parasitic and bacterial infections
Simmons Addressing the data challenge
Park et al. Retinal attenuates inflammatory arthritis by reciprocal regulation of IL-17-producing T cells and Foxp3+ regulatory T cells and the inhibition of osteoclastogenesis
Haghmorad et al. Oral Administration of Myelin Oligodendrocyte Glycoprotein Attenuates Experimental Autoimmune Encephalomyelitis through Induction of Th2/Treg Cells and Suppression of Th1/Th17 Immune Responses
Ford et al. CD8+ T cell clonotypes from prior SARS-CoV-2 infection predominate during the cellular immune response to mRNA vaccination (preprint)
Ning et al. Therapeutic activation of virus-specific resident memory T cells within the glioblastoma microenvironment
Yoshimura et al. Mechanisms for bone resorption induced by periodontal pathogens
Yi Affective Computing
Maskalan et al. Identification of the novel HLA-A* 01: 200 allele by sequence-based typing in a Croatian individual
WO2008102799A1 (en) Information management system, information management method and information management program
Sherri et al. Epstein–Barr Virus DNA Exacerbates Arthritis in a Mouse Model via Toll-like Receptor 9
Petazzi Methyl-CpG binding protein 2 deregulation: from Rett syndrome to MeCP2 duplication disorder
Silva et al. Towards the detection of deception in interactive multimedia environments

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12826702

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12826702

Country of ref document: EP

Kind code of ref document: A2